90钇玻璃微球治疗肝癌的临床研究

探讨＾９０钇玻璃微球治疗肝癌的临床效果。材料与方法，１９９６年８月至１９９８年５月，应用＾９０钇治疗肝癌１７例，采用含有＾９０钇的三明治疗法：首先注入＾９０钇和超注化碘油悬浮液，然后注入三联合化疗药，最后用明胶海绵颗粒栓塞。对其中１２例施行了经皮股动脉药盒导管系统植入，并对操作技术进行了改进。

Hepatic Radioembolization with Yttrium-90 Glass Microspheres for the Treatment of Primary Liver Cancer

Objective: To evaluate the clinical effects of hepatic radioembolization with Yttrium90 (90Y) glass microspheres for the treatment of primary liver cancer. Materials and Methods: Hepatic radioembolization was performed in 17 patients with liver cancer during the period of Aug 1996May 1998. The following sandwich form injection procedure was used. After the suspension of 90Y with ultrafluid lipiodol was injected, three chemotherapeutic agents were administered via hepatic artery, then the hepatic arteries were embolized with Gelfoam particles. Percutaneous portcatheter system (PCS) implantation via femoral artery was performed in 12 cases. Results: The tumor took more 90Y than normal liver in a ratio of 2.41. On CT scan, significant reduction of the tumor size was seen in 11 cases. The average survival period was 19.5 months. In all 12 cases with PCS, the catheters remained patency and no catheter tip dislocation occurred. Conclusion: 90Y glass microspheres is one of the most effective radioisotope for the treating of liver cancer, both primary and metastatic, especially effective for the localized and hypervascular lesion. Hepatic arterioportal shunt should not be considered as a contraindication for radioembolization therapy. The percutaneous PCS implantation via femoral artery offers a permanent access for 90Y injection and other interventional procedures.